Gadolinium and nephrogenic systemic fibrosis

Kidney International

Volumn 72, Issue 3, 2007, Pages 260-264

  Grobner, T ^a   Prischl, F C ^b  

^a General Hospital Wiener Neustadt   (Austria)

^b Klinikum Kreuzschwestern Wels   (Austria)

Author keywords

Chronic renal failure, complication; Gadolinium containing contrast agents; Nephrogenic systemic fibrosis

Indexed keywords

COLLAGEN; GADODIAMIDE; GADOLINIUM;

DISEASE ASSOCIATION; DISEASE COURSE; ELASTIC FIBER; FIBROBLAST; HISTOPATHOLOGIC SKIN REACTION; HUMAN; KIDNEY DISEASE; NEPHROGENIC FIBROSING DERMOPATHY; NEPHROGENIC SYSTEMIC FIBROSIS; NEPHRON; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY; SKIN BIOPSY; SKIN CULTURE; SKIN MANIFESTATION;

CONTRAST MEDIA; FIBROSIS; GADOLINIUM; HUMANS; KIDNEY; KIDNEY FAILURE; MAGNETIC RESONANCE IMAGING; SCLERODERMA, SYSTEMIC; SKIN;

EID: 34547477080     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002338     Document Type: Short Survey

References (31)

1. Leboit PE. What nephrogenic fibrosing dermopathy might be. Arch Dermatol 2003; 139: 928-930.
2. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003; 139: 903-906.
3. Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: Report of a new case with literature review. Am J Kidney Dis 2005; 46: 754-759.
4. Cowper SE, Su L, Robin H et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001; 23: 383-393.
5. Swartz RD, Crofford LJ, Phan SH et al. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 2003; 114: 563-572.
6. Cowper SE, Robin HS, Steinberg HM et al. Scleromyxedema-like cutaneous disease in renal-dialysis patients. Lancet 2000; 356: 1000-1001.
7. Swaminathan S, Ahmad I, McCarthy JT et al. Nephrogenic fibrosing dermopathy and high dose erythropoetin therapy. Ann Intern Med 2006; 145: 234-235.
8. Fazeli A, Lio PA, Liu V. Nephrogenic fibrosing dermopathy: are ACE inhibitors the missing link? Arch Dermatol 2004; 140: 1401 (letter).
9. Mackay-Wiggan JM, Cohen DJ, Hardy MA et al. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). Am Acad Dermatol 2003; 48: 55-60.
10. Cowper SE. Nephrogenic fibrosing dermopathy: the first six years. Curr Opin Rheumatol 2003; 15: 785-790.
11. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21: 1104-1108. (Erratum in Nephrol Dial Transplant 2006; 21: 1745).
12. Marckmann P, Skov L, Rossen K et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17: 2359-2362.
13. Food and Drug Administration Public Health Advisory: gadolinium- containing contrast agents for magnetic resonance imaging (MRI): Omniscan, Opti MARK, Magnevist, ProHance, and MultiHance. (Updated 8 January 2007) 2006. Available at http://www.fda.gov/cder/drug/advisory/gadoliniumagents.htm.Accessed 12 April 2007.
14. Evans C. Biochemistry of the Lanthanides. Plenum Press: New York, 1990.
15. Weinmann HJ, Brasch RC, Press WR, Wesbey GE. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. Am J Roentgenol 1984; 142: 619-624.
16. Barnhardt JLKN, Bakan DA, Berk RN. Biodistribution of GdCl3 and Gd-DTPA and their influence on proton magnetic relaxation in rat tissues. Magn Reson Imaging 1987; 5: 221-231.
17. Lazar G. The reticuloendothelial-blocking effect of rare earth metals in rats. J Reticuloendothel Soc 1973; 13: 231-237.
18. Cheng Y, Huijing Y, Huakuan L et al. The events relating to lanthanide ions enhanced permeability of human erythrocyte membrane: binding, conformational change, phase transition and ion transport. Chem-Biol Interact 1999; 121: 267-289.
19. Prince MR, Erel HE, Lent RW et al. Gadodiamide administration causes spurious hypocalcemia. Radiology 2003; 227: 639-646.
20. Uggeri F, Aime S, Anelli PL et al. Novel contrast agents for magnetic resonance imaging. Synthesis and characterisation of the ligand BOPTA and its Ln(III) complexes. Inorg Chem 1995; 34: 633-642.
21. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998; 5: 491-502.
22. Okada S, Katagiri K, Kumazaki T, Yokoyama H. Safety of gadolinium contrast agent in hemodialysis patients. Acta Radiol 2001; 42: 339-341.
23. Mann JS. Stability of gadolinium complexes in vitro and in vivo. J Comput Assist Tomogr 1993; 17: S19-S23.
24. Vorobiov M, Basok A, Tovbin D et al. Iron-mobilizing properties of the gadolinium-DTPA complex: clinical and experimental observations. Nephrol Dial Transplant 2003; 18: 884-887.
25. Behra-Miellet J, Gressier B, Brunet C et al. Free gadolinium and gadodiamide, a gadolinium chelate used in magnetic resonance imaging: evaluation of their in vitro effects on human neutrophil viability. Methods Find Exp Clin Pharmacol 1996; 18: 437-442.
26. Thomsen HS, (ed) Contrast Media. Safety Issues and ESUR Guidelines. Springer: Berlin, Heidelberg, New York, 2006.
27. Broome DR, Girguis MS, Baron PW et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Am J Radiol 2007; 188: 1-7.
28. Evenepoel P, Zeegers M, Segaert S et al. Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure. Nephrol Dial Transplant 2004; 49: 469-473.
29. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007; 56(1): 27-30.
30. High WA, Ayers RA, Chandler J et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56(1): 21-26.
31. Quan TE, Cowper S, Wu SP et al. Circulating fibrocytes: collagen secreting cells of the peripheral blood. Int J Biochem Cell Biol 2004; 36: 598-606.